Surabhi Dangi-Garimella, PhD

The new test, developed by Dako, will provide information on the survival benefit of patients with non-squamous NSCLC treated with nivolumab.

A new study published in JAMA Oncology has identified disparate survival outcomes across sites of care.

With the final guidance expected in November, UK will follow Europe in the use of pembrolizumab in treating advanced melanoma patients refractory to previous treatment as well as those who have not been previously treated.

A new study published in the journal BMJ Innovations that surveyed doctors and nurses in the United Kingdom has found routine breach of patient privacy through the use of digital devices.

A retrospective follow-up in women who had received grafts of cryopreserved ovarian tissue discovered a 30% success rate in bearing a child.

Tumors caught early have a lower probability of advancing to the lymph nodes and improve patient outcomes, the BMJ study found.

Price transparency continues to plague healthcare, as this new report from Castlight Health suggests.

As HIV-infected adults live longer, they are increasingly susceptible to specific cancer types. This calls for targeted cancer prevention efforts in this population.

A multistakeholder approach to patient assistance programs was the topic of discussion at ACCC's first annual ICLIO meeting in Philadelphia.

The evidence of weight-loss improving overall well-being and predisposition to chronic as well as acute conditions is mounting. We now need coverage policies that can help patients take advantage of weight loss procedures.

Reimbursement remains a primary concern with the new immuno-oncology agents. Who pays and how do you ensure payment was fervently discussed by oncologists at the recent ICLIO meeting hosted by the Association of Community Cancer Centers.

A study reports that despite the steady growth in hospital-based palliative care programs, access is sketchy and is driven by geographic location and hospital ownership.

A government-funded network of specialized survivor clinics in Ontario, Canada, significantly decreased emergency department visits among adult survivors of childhood cancer.

This approval marks the first-ever for 2 immuno-oncology agents in cancer treatment.

The result of a multicollaborative effort, the study published in the Journal of Clinical Oncology found that incorporating breast density information in the risk calculator could accurately estimate women's risk for the disease.

A study published in BMJ measured the prevalence, annual compensation, and beneficial stock ownership of directors from publicly traded healthcare companies who had academic affiliations.

An NCI-funded Breast Cancer Surveillance Consortium study has found that computer-aided detection and interpretation of mammograms does not add any value to breast cancer screening.

A prospective study that enrolled more than 10,000 women with hormone-receptor—positive, HER2-negative breast cancer has found that their response to a 21-gene test can identify patients who can avoid chemotherapy.

Data presented at the ongoing European Cancer Congress has identified a different epigenetic profile in the tumors of younger colorectal cancer patients, information that can help improve treatment options in this population.

Developed by Inovio Pharmaceuticals, the vaccine has shown the potential to impact precancerous cervical lesions.

The trial, conducted in France, was a proof-of-concept study to evaluate the efficacy of targeted agents in patients, based on their tumor's molecular profile.

In a letter to Pathway Genomics, the FDA has expressed interest in discussing the company's validation strategy as well as evaluating data on clinical sensitivity and specificity of the CancerIntercept Detect test.

A study published in The Journal of Urology suggests the Grade D recommendation for PSA-based screening may place those with intermediate and high-risk prostate cancer at risk.

A JAMA Internal Medicine study found the terms "breakthrough" and "promising" raised people's expectations on the drug's performance as opposed to when the drugs were described as having met the breakthrough criteria.

Research primarily at Virginia Commonwealth University focuses on a key regulator of metabolic diseases as well as cancer.

A white paper released by QuantiaMD has identified a lack of awareness and education about biosimilars among prescribing physicians.

Lonsurf (TAS-102) is an oral 2-drug combination pill that is intended for metastatic colorectal cancer patients who have failed on chemotherapy and biological therapy.

AstraZeneca hopes to harness the open source platform of the DREAM challenge, releasing preclinical data to discover synergistic cancer drug combinations.

Among other challenges faced by cancer care centers, reimbursement for providing patient-centered care services remains at the top, a survey by The Association of Community Cancer Centers found.

A report in The New York Times identifies challenges that could be raised based on Califf's past associations with the drug industry.